We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Non-Invasive Prediction of Colorectal Neoplasia (NIPCON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01815463
Recruitment Status : Terminated (Local PI did not submit annual renewal, still active in Detroit, not recruiting.)
First Posted : March 21, 2013
Last Update Posted : September 27, 2016
Information provided by (Responsible Party):
Martin Tobi, Corporal Michael J. Crescenz VA Medical Center

Brief Summary:

Hypothesis:The Adnab-9 antigen is a predictive biomarker in individuals at risk of developing colorectal neoplasia.

Study aim is to evaluate the potential of the Adnab-9 monoclonal antibody (MAb) as a marker of cancer risk in a population at increased risk for colorectal cancer (CRC). This marker would be compared to other current and emerging diagnostic methods. 2,800 Veterans would be recruited into the study. In phase 1, candidates would be defined as having increased CRC risk by a short questionnaire. Stool samples would be obtained and a semi-quantitative Adnab-9 antigen assay (ELISA) would be determined. Patients with differing high and low estimations of fecal Adnab-9 would undergo colonoscopy at which time other samples of effluent and colonic mucosa would be taken, and a detailed lifestyle and nutritional questionnaire would be completed. The characteristics of the Adnab-9 fecal test as a diagnostic test would be critically determined using the outcome of the colonoscopic and other test results. The patients will be contacted through the mail and by word of mouth. Informed consent will be obtained before the samples are obtained. The participants are clinically defined as high-risk and therefore screening colonoscopy would be likely performed in any event. A number of assays for Adnab-9 are feasible including slot-blot, Western blot, and ELISA. Other stool studies include conventional fecal occult blood tests (FOBT or FIT) that will be performed in tandem. The investigators therefore began this method of collection and obtained consent from over 2000 patients with a similar overall compliance rate with FOBT screening procedures to that reported previously of approximately 50%. Currently the study is no longer enrolling patients at the Detroit VA and is now finalizing data entry. Another 450 patients to be recruited at the Philadelphia VAMC.

Condition or disease
Colonic Polyps Polyposis Coli Colorectal Cancer

Detailed Description:
The primary objectives is to test the efficacy of Adnab-9 stool testing in a population at high-risk for colorectal neoplasia and directly compare it to that of the FOBT and secondarily, identify the source of the Adnab-9 antigen to determine influences of diet and environment on its expression. The design is a prospective cross sectional (Part 1) and a case-control longitudinal follow-up study (Part 2) using a brief questionnaire to assess risk for cancer in a total of 2800 Part I patients will be enrolled designed to achieve a database of high risk individuals and measure fecal Adnab-9 levels before a clinically indicated colonoscopy is performed. The patients submit 4 FOBT cards in a routine manner by mail, 3 are used for the FOBT and stool is extracted from the last card for the Adnab-9 ELISA which is reported as OD/5ug protein/well. 100 Part 2 enrollees are then selected on the basis of positive fecal Adnab-9 test candidates matched with a like number of patients with negative stool results who have had their initial colonoscopy and who will have a 5-year follow-up colonoscopy. Detailed Adnab-9 testing (immunohistochemical Adnab-9 binding; blood biomarker estimations and Adnab-9 Western blotting) will be performed on various bodily fluids to perfect the method of testing and completion of the detailed questionnaire to check for reproducibility and interim lifestyle changes in these participants.

Layout table for study information
Study Type : Observational
Actual Enrollment : 2282 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Non-Invasive Prediction of Colorectal Neoplasia
Study Start Date : August 2006
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2014

colorectal neoplasia
No interventions Record colorectal neoplasia

Primary Outcome Measures :
  1. Correlation of Adnab-9 stool result with outcome of colonoscopy [ Time Frame: 10 years ]
    Stool is collected on guaiac stool cards and/or stool Polymedco sample bottle and extracted. Extracted stool is assayed for protein content and this is used as a standard for the Adnab-9 ELISA. Record review note colonoscopy outcome which is correlated with Adnab-9 ELISA result.

Secondary Outcome Measures :
  1. Define the origin of the Adnab-9 bound antigen [ Time Frame: 10 years ]
    Biopsies are taken at the time of colonoscopy in ~10% of initial enrollees, from 6 colonic segments. In addition colonic effluent. saliva, urine and blood samples are taken. ELISA and immunohistochemistry for Adnab-9 binding are performed.

Biospecimen Retention:   Samples With DNA
Stool Urine Saliva Blood Tissue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Greater than average risk for colorectal neoplasia

Inclusion Criteria:

  • ability to complete a consent form
  • must be at above average risk for colorectal neoplasia
  • physically able to undergo colonoscopy or barium enema

Exclusion Criteria:

  • Mentally handicapped
  • Physically infirm
  • Low risk for colorectal neoplasia
  • Pregnant individuals
  • Vulnerable populations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01815463

Layout table for location information
United States, Pennsylvania
Philadelphia VAMC
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Corporal Michael J. Crescenz VA Medical Center
Layout table for investigator information
Principal Investigator: Martin Tobi, MB,ChB Philadelphia VAMC (WOC) Detroit VAMC (WOC) Saginaw VAMC
Principal Investigator: Fadi Antaki, MD Detroit VAMC
Principal Investigator: John Lieb, MD Philadelphia PVAMC
Layout table for additonal information
Responsible Party: Martin Tobi, MB ChB, Corporal Michael J. Crescenz VA Medical Center
ClinicalTrials.gov Identifier: NCT01815463    
Other Study ID Numbers: 00919
0409000159 ( Other Grant/Funding Number: 096294M1F )
First Posted: March 21, 2013    Key Record Dates
Last Update Posted: September 27, 2016
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Martin Tobi, Corporal Michael J. Crescenz VA Medical Center:
monoclonal antibody
barium enema
flexible sigmoidoscopy
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenomatous Polyposis Coli
Colonic Polyps
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Intestinal Polyps
Pathological Conditions, Anatomical
Adenomatous Polyps
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplastic Syndromes, Hereditary
Intestinal Polyposis
Genetic Diseases, Inborn